Official reprint from UpToDate®

www.uptodate.com ©2020 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Overview of homocysteine
Authors: Robert S Rosenson, MD, C Christopher Smith, MD, Kenneth A Bauer, MD
Section Editor: Mason W Freeman, MD
Deputy Editor: Jane Givens, MD

All topics are updated as new evidence becomes available and our peer review process is complete.

Literature review current through: Dec 2019. | This topic last updated: Nov 13, 2019.

INTRODUCTION

Homocysteine is an intermediary amino acid formed by the conversion of methionine to

cysteine (figure 1). Homocystinuria is a rare autosomal recessive disorder characterized by
severe elevations in plasma and urine homocysteine concentrations. Clinical manifestations of
homocystinuria include developmental delay, Marfanoid appearance, osteoporosis, ocular
abnormalities, thromboembolic disease, and severe premature atherosclerosis.

Less marked elevations in plasma homocysteine are much more common, occurring in 5 to 7
percent of the population [1,2]. Although unassociated with the clinical stigmata of
homocystinuria, moderate hyperhomocysteinemia was considered an independent risk marker
for atherosclerotic vascular disease and for venous thromboembolism (VTE). However,
associations between plasma homocysteine and vascular complications, particularly VTE, may
have been due to failure to take into account confounding risk factors. (See 'Disease
associations' below.)

This topic will review hyperhomocysteinemia as a risk marker for vascular disease and whether
or not to test for or treat elevated homocysteine levels.

ETIOLOGY OF HYPERHOMOCYSTEINEMIA

Homocysteine is metabolized by one of two pathways: transsulfuration and remethylation

(figure 1). Vitamins are necessary in the metabolism of homocysteine. The transsulfuration of
homocysteine to cysteine is catalyzed by cystathionine-beta-synthase, a process that requires
pyridoxal phosphate (vitamin B6) as a cofactor. Remethylation of homocysteine produces
methionine. This reaction is catalyzed either by methionine synthase or by betaine-
homocysteine methyltransferase. Vitamin B12 (cobalamin) is the precursor of methylcobalamin,
which is the cofactor for methionine synthase.

Elevations in plasma homocysteine levels can result from:

● Genetic factors – The most common form of genetic hyperhomocysteinemia results from
production of a thermolabile variant of methylene tetrahydrofolate reductase (MTHFR) with
reduced enzymatic activity (T mutation) (figure 1) [3]. The responsible gene is common; in
the United States, approximately 30 percent of the population is heterozygous for the
thermolabile variant of MTHFR and 10 percent is homozygous [4]. Homozygosity for the
thermolabile variant of MTHFR (TT genotype) is a relatively common cause of elevated
plasma homocysteine levels in the general population, often occurring in association with
low serum folate levels [5-7]. At any given level of folate intake, TT homozygotes have
lower plasma folate levels than nonhomozygotes [8].

● Vitamin deficiencies – Increased blood levels of homocysteine may reflect deficiency of

folate, vitamin B6, or vitamin B12 [9-12]. Plasma folate and B12 levels, in particular, are
strong determinants of the homocysteine concentration. Homocysteine levels are inversely
related to folate consumption, reaching a stable baseline level when folate intake exceeds
400 microg/day [13-15]. Vitamin B6 is a weaker determinant of homocysteine levels [14].

The importance of vitamin deficiency in the pathogenesis of hyperhomocysteinemia was

evaluated in a cohort of 1041 older adults [13]. Two-thirds of patients with elevated
homocysteine levels had a subnormal plasma concentration of folate, vitamin B12, or
pyridoxal-5-phosphate (the coenzyme form of vitamin B6). The prevalence of low plasma
B12 levels was higher in this cohort than in a European case-control study with younger
patients [14]. These data suggest that suboptimal B12 intake coupled with decreased
absorption might play a greater role in elevating homocysteine and subsequent coronary
heart disease (CHD) risk in older adults than in younger patients. By contrast, folate intake
low enough to raise plasma homocysteine may be relatively common in the general
population, particularly in moderate consumers of alcohol.

Further evidence of the importance of vitamin deficiency comes from a report that
assessed the results of the US Food and Drug Administration (FDA) regulation requiring all
enriched grain products be fortified with folic acid. Patients who had blood tested following
fortification had significantly higher blood folate concentrations and lower homocysteine
concentrations [16]. In addition, the prevalence of a high homocysteine concentration (>13
micromol/L) decreased from 18.7 percent before fortification to 9.8 percent after
fortification.

● Chronic kidney disease – Chronic kidney disease can increase homocysteine levels due
to decreased renal removal and impaired metabolism. (See "Secondary prevention of
 cardiovascular disease in end-stage renal disease (dialysis)", section on
'Hyperhomocysteinemia'.)

● Drugs – Some drugs used in the treatment of hypercholesterolemia, such as fibrates and
nicotinic acid, can raise homocysteine levels by approximately 30 percent; however, the
clinical significance of this is uncertain [17-19]. Metformin has also been associated with
increases in homocysteine levels [20], as has methotrexate [17].

● Smoking – Cigarette smoking may elevate homocysteine levels [21].

DISEASE ASSOCIATIONS

Markedly elevated levels of homocysteine in the blood have primary atherogenic and
prothrombotic properties [2,22-38]. Histopathologic hallmarks of homocysteine-induced
vascular injury include intimal thickening, elastic lamina disruption, smooth muscle hypertrophy,
marked platelet accumulation, and the formation of platelet-enriched occlusive thrombi [39-43].
These observations were presumed to explain the association between mild
hyperhomocysteinemia and the diseases described below.

Vascular disease — Elevated homocysteine levels have been associated with an increased
risk of cardiovascular and cerebrovascular disease. However, unlike modifiable risk factors
such as hypertension, hypercholesterolemia, smoking, and diabetes, it has not been shown that
lowering homocysteine prevents cardiovascular events [44]. (See 'Patients with cardiovascular
disease or venous thromboembolism' below and "Overview of established risk factors for
cardiovascular disease".)

The association of elevated homocysteine with cardiovascular disease and stroke was
illustrated by a meta-analysis that evaluated data from 12 prospective studies, involving 1855
coronary heart disease (CHD) events and 463 stroke events [45]. After adjustment for known
cardiovascular risk factors, a 25 percent lower homocysteine level (approximately 3 micromol/L)
was associated with a lower risk of ischemic heart disease risk (odds ratio [OR] 0.89, 95% CI
0.83-0.86) and stroke (OR 0.81, 95% CI 0.69-0.95). Another meta-analysis performed for the
US Preventive Services Task Force (USPSTF) specifically examined the issue of whether or not
homocysteine levels add predictive value when estimating the risk of new-onset CHD [46]. The
analysis found that, independent of Framingham risk factors, each 5 micromol/L higher
homocysteine level was associated with a 20 percent greater risk of CHD.
Hyperhomocysteinemia has also been associated with lower-extremity peripheral arterial
disease and heart failure [47,48].

Genetic studies, whereby individuals with genetically determined elevations in plasma

homocysteine are examined, have reported inconsistent findings about risk for cardiovascular
disease [49-51]. As an example, in one meta-analysis of 40 observational studies involving
11,162 patients who were homozygous for the thermolabile variant of methylene
tetrahydrofolate reductase (MTHFR, which produces higher homocysteine levels) and 12,758
matched controls, the MTHFR TT genotype was associated with a higher risk for CHD (OR
1.16, 95% CI 1.05-1.28) [49]. However, a subsequent meta-analysis of genome-wide
association studies including 31,400 cases and 92,927 controls found no association between a
genetic risk score of homocysteine-regulating genes and CHD, although plasma homocysteine
levels were lacking in most individuals [51].

Venous thromboembolism — Hyperhomocysteinemia has been associated with venous

thromboembolism (VTE) in some but not all studies [52-58].

Meta-analyses of case-control studies have found an odds ratio of 2.5 to 3.0 for VTE in patients
with markedly elevated homocysteine levels of more than two standard deviations above the
mean value of control groups [53,54]. Moderate hyperhomocysteinemia (15 to 30 micromol/L)
may also be a risk marker for recurrent VTE. This was reported in a multicenter study in which
patients with a single episode of idiopathic VTE were prospectively followed after
discontinuation of oral anticoagulants [55]. Recurrent VTE was significantly more likely in the 66
patients with hyperhomocysteinemia than in the 198 patients with normal homocysteine levels
(18.2 versus 8.1 percent).

Additional research, however, has concluded that perceived associations between mild
hyperhomocysteinemia and VTE may have been due to confounding [56-58]. In a large case-
control study of over 3000 individuals, for example, mild hyperhomocysteinemia was associated
with venous thrombosis in models adjusted for age and sex but not after also controlling for
body mass index (BMI) and smoking status [58].

Obstetric complications — An early report linked the thermolabile variant of MTHFR to

obstetric complications such as severe preeclampsia, abruptio placentae, fetal growth
restriction, neural tube defects, and stillbirth [59,60]. However, a 2006 meta-analysis of 26
studies of 2120 women with unexplained recurrent pregnancy loss and 2949 controls did not
find that the MTHFR C677T genotype was a risk factor for this outcome, except in a Chinese
population [61].

Other — Hyperhomocysteinemia is also associated with other disorders:

● Osteoporosis – High homocysteine levels in adults have been associated with osteoporotic
fractures in some [62-64], but not all [65], studies.

In a trial of homocysteine-lowering therapy with folate and B12 in adults at high risk for
cardiovascular disease, there was no reduction in vertebral or nonvertebral fractures,
although baseline homocysteine levels were not elevated in the study population [66]. (See
"Overview of the management of osteoporosis in postmenopausal women", section on
'Therapies not recommended'.)
 ● Dementia – Hyperhomocysteinemia is associated with higher rates of dementia [67];
however, there is no convincing evidence that lowering homocysteine levels prevents or
treats dementia [68]. (See "Risk factors for cognitive decline and dementia", section on
'Homocysteine'.)

● Several studies report an association of elevated homocysteine with cognitive impairment

in Parkinson disease [69,70].

DECISION TO TEST

In general, we only measure serum homocysteine in patients suspected of having

homocystinuria but not in other clinical settings.

Patients with suspected homocystinuria — We measure homocysteine levels in patients

with suspected homocystinuria and in first-degree relatives of patients with homocystinuria.

Homocystinuria is suspected in children and adolescents with characteristic physical findings,

developmental delay, or cardiovascular disease or thromboembolism. It is occasionally
diagnosed in young adults [71]. Patients with homocystinuria have markedly elevated serum
and urine homocysteine.

Homocystinuria is a rare autosomal recessive disorder. Clinical manifestations of

homocystinuria include developmental delay, Marfanoid appearance, osteoporosis, ocular
abnormalities (ectopia lentis), thromboembolic disease, and severe premature atherosclerosis.
Routine newborn screening can detect homocystinuria but is not universally available.

Patients with cardiovascular disease or venous thromboembolism — Interventions to

lower homocysteine have not been shown to prevent cardiovascular disease or venous
thromboembolism (VTE) [44,72-77]. In addition, as outlined above, the association between
mild hyperhomocysteinemia and VTE may be due to confounding. Accordingly, we generally do
not measure homocysteine levels in patients with vascular disease or VTE. Our approach is
based upon trial evidence that lowering homocysteine levels with vitamin supplementation does
not improve clinical outcomes. However, these trials were conducted in countries with folic acid
fortification of the food supply and primarily among participants who were not required to have
elevated plasma homocysteine at baseline. In addition, these trials were designed to lower
homocysteine concentrations with folic acid, but participants with normal folic acid levels were
not excluded [15].

Lowering homocysteine levels has not been shown to prevent future cardiovascular events,
with the possible exception of stroke [44,72,74]. The best data come from a meta-analysis of 15
randomized trials including 71,422 participants which found that, compared with placebo,
homocysteine-lowering therapy (folate, vitamin B12, and/or vitamin B6) failed to reduce the risk
of myocardial infarction (7.1 versus 6.0 percent), all-cause mortality (11.7 versus 12.3 percent),
or serious adverse events (8.3 versus 8.5 percent) [44]. Homocysteine-lowering therapy
modestly reduced the incidence of stroke compared with placebo (4.3 versus 5.1 percent),
although this finding was largely influenced by a single Chinese study [78].

As with cardiovascular disease, lowering homocysteine has not been shown to reduce rates of
recurrent VTE. The best data come from a randomized trial of homocysteine-lowering with daily
B vitamins (folic acid 5 mg, vitamin B6 50 mg, vitamin B12 0.4 mg) in 701 patients with a first
episode of VTE [76]. There was no statistically significant reduction in recurrent VTE in patients
treated with B vitamins (hazard ratio [HR] 0.84, 95% CI 0.56-1.26). There was also no reduction
in recurrent VTE in the 360 patients with baseline homocysteine levels above the 75th
percentile (HR 1.14, 95% CI 0.65-1.98), or in the 341 patients with normal homocysteine levels
(HR 0.58, 95% CI 0.31-1.07). A post hoc subgroup analysis of a second trial reached similar
conclusions [77].

Patents without known vascular disease — Patients without known vascular disease may
ask to have their homocysteine levels checked as part of risk stratification for cardiovascular
disease. Given the lack of evidence for benefit from lowering elevated homocysteine levels in
patients with established cardiovascular disease, we do not measure homocysteine levels in
patients without known vascular disease.

LABORATORY MEASUREMENT OF HOMOCYSTEINE

Sensitive assays allow quantification of the total homocysteine concentration; approximately 75

to 85 percent is protein-bound and 15 to 25 percent is in acid-soluble free forms [79].
Processing of specimens for homocysteine measurement requires cooling the specimen in wet
ice and prompt transfer to the laboratory to minimize delays in processing. Delays in processing
contribute to falsely elevated homocysteine levels [80].

Normal homocysteine concentrations range between 5 and 15 micromol/L.

Hyperhomocysteinemia has been classified as follows [81]:

● Moderate (15 to 30 micromol/L)

● Intermediate (30 to 100 micromol/L)
● Severe (>100 micromol/L)

TREATMENT

As described above, the available evidence suggests not testing for or treating
hyperhomocysteinemia unless homocystinuria is suspected or confirmed. In the rare patient
with severe hyperhomocysteinemia associated with homocystinuria, we recommend referral to
both a specialist in metabolic diseases and a nutritionist. (See 'Decision to test' above.)

The majority of hyperhomocysteinemia is caused by low levels of folate and vitamin B12 in
patients with or without the thermolabile variant of methylene tetrahydrofolate reductase
(MTHFR). (See 'Etiology of hyperhomocysteinemia' above.)

Correcting nutritional inadequacy of folic acid and vitamin B12 will lower homocysteine levels in
most patients [82]. A diet rich in fruits, vegetables, and low-fat dairy products and low in
saturated and total fat also can lower serum homocysteine [83].

In many countries, grains are fortified with folic acid, which leads to higher folate levels across
the population. As an example, mandatory folic acid fortification of cereal grains in the United
States led to a more than twofold increase in mean serum folate levels in a nationally
representative survey [84].

SUMMARY AND RECOMMENDATIONS

● Homocysteine is an intermediary amino acid formed by the conversion of methionine to

cysteine. Elevations in plasma homocysteine are common, occurring in 5 to 7 percent of
the population. (See 'Introduction' above.)

● Homocysteine is metabolized by one of two pathways: transsulfuration and remethylation

(figure 1). Vitamins are necessary in the metabolism of homocysteine. Elevations in plasma
homocysteine levels can result from genetic factors, most commonly a thermolabile variant
of methylene tetrahydrofolate reductase (MTHFR) with reduced enzymatic activity (T
mutation); vitamin deficiencies, specifically deficiency of folate, vitamin B6, or vitamin B12;
chronic kidney disease, which can increase homocysteine levels due to decreased renal
removal and impaired metabolism; certain drugs, including fibrates, nicotinic acid,
metformin, and methotrexate; and cigarette smoking. (See 'Etiology of
hyperhomocysteinemia' above.)

● Homocystinuria, a rare condition detected by newborn screening in many regions, presents

in children and adolescents with developmental delay, Marfanoid appearance,
osteoporosis, ocular abnormalities (ectopia lentis), thromboembolic disease, severe
premature atherosclerosis, and extreme elevations in plasma homocysteine. In the rare
patient with severe hyperhomocysteinemia associated with homocystinuria, we
recommend referral to both a specialist in metabolic diseases and a nutritionist. (See
'Decision to test' above and 'Treatment' above.)

● Moderately elevated homocysteine levels have been associated with an increased risk of
cardiovascular and cerebrovascular disease, venous thromboembolic disease, and
 obstetric complications. In experimental studies, homocysteine has primary atherogenic
and prothrombotic properties, suggesting a possible mechanism for these associations.
(See 'Disease associations' above.)

● Despite some limitations, clinical trials have generally found that reducing levels of
homocysteine with B vitamin supplementation does not prevent cardiovascular disease or
reduce the incidence of recurrent venous thromboembolism (VTE) or arterial thrombosis.
Thus, we suggest not testing for or treating hyperhomocysteinemia (Grade 2B), unless
homocystinuria is suspected or confirmed. (See 'Patients with cardiovascular disease or
venous thromboembolism' above.)

ACKNOWLEDGMENT

The editorial staff at UpToDate would like to acknowledge David Kang, MD, PhD, who
contributed to an earlier version of this topic review.

Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

1. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma
levels in health, disease, and drug therapy. J Lab Clin Med 1989; 114:473.

2. McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2:386.

3. Kang SS, Wong PW, Susmano A, et al. Thermolabile methylenetetrahydrofolate

reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991;
48:536.

4. https://www.cdc.gov/genomics/population/genvar/frequencies/mthfr.htm.

5. Guttormsen AB, Ueland PM, Nesthus I, et al. Determinants and vitamin responsiveness of
intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hordaland
Homocysteine Study. J Clin Invest 1996; 98:2174.

6. Harmon DL, Woodside JV, Yarnell JW, et al. The common 'thermolabile' variant of
methylene tetrahydrofolate reductase is a major determinant of mild
hyperhomocysteinaemia. QJM 1996; 89:571.

7. Kluijtmans LA, Young IS, Boreham CA, et al. Genetic and nutritional factors contributing to
hyperhomocysteinemia in young adults. Blood 2003; 101:2483.
 8. de Bree A, Verschuren WM, Bjørke-Monsen AL, et al. Effect of the
methylenetetrahydrofolate reductase 677C-->T mutation on the relations among folate
intake and plasma folate and homocysteine concentrations in a general population
sample. Am J Clin Nutr 2003; 77:687.

9. Robinson K, Arheart K, Refsum H, et al. Low circulating folate and vitamin B6

concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery
disease. European COMAC Group. Circulation 1998; 97:437.

10. Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in
relation to risk of coronary heart disease among women. JAMA 1998; 279:359.

11. Voutilainen S, Rissanen TH, Virtanen J, et al. Low dietary folate intake is associated with
an excess incidence of acute coronary events: The Kuopio Ischemic Heart Disease Risk
Factor Study. Circulation 2001; 103:2674.

12. Vermeulen EG, Stehouwer CD, Twisk JW, et al. Effect of homocysteine-lowering
treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a
randomised, placebo-controlled trial. Lancet 2000; 355:517.

13. Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary
determinants of homocysteinemia in an elderly population. JAMA 1993; 270:2693.

14. Ubbink JB, Vermaak WJ, van der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and
folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993; 57:47.

15. Kang SS, Rosenson RS. Analytic Approaches for the Treatment of
Hyperhomocysteinemia and Its Impact on Vascular Disease. Cardiovasc Drugs Ther
2018; 32:233.

16. Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma
folate and total homocysteine concentrations. N Engl J Med 1999; 340:1449.

17. Desouza C, Keebler M, McNamara DB, Fonseca V. Drugs affecting homocysteine

metabolism: impact on cardiovascular risk. Drugs 2002; 62:605.

18. Rosenson RS. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis 2003;

171:87.

19. Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid-lowering drugs on
plasma homocysteine levels. Expert Opin Drug Saf 2004; 3:101.

20. Zhang Q, Li S, Li L, et al. Metformin Treatment and Homocysteine: A Systematic Review

and Meta-Analysis of Randomized Controlled Trials. Nutrients 2016; 8.
21. Bazzano LA, He J, Muntner P, et al. Relationship between cigarette smoking and novel
risk factors for cardiovascular disease in the United States. Ann Intern Med 2003;
138:891.

22. Poddar R, Sivasubramanian N, DiBello PM, et al. Homocysteine induces expression and
secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic
endothelial cells: implications for vascular disease. Circulation 2001; 103:2717.

23. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease.
Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler
Thromb Vasc Biol 1997; 17:2074.

24. Al-Obaidi MK, Philippou H, Stubbs PJ, et al. Relationships between homocysteine, factor
VIIa, and thrombin generation in acute coronary syndromes. Circulation 2000; 101:372.

25. Nappo F, De Rosa N, Marfella R, et al. Impairment of endothelial functions by acute

hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999; 281:2113.

26. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to

its endothelial cell membrane receptor. J Clin Invest 1993; 91:2873.

27. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced

vascular endothelial cell activator. J Clin Invest 1986; 77:1909.

28. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C
activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88:1906.

29. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses

anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J
Clin Invest 1993; 92:1381.

30. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor

activity of thrombomodulin and enhances thrombomodulin expression in human umbilical
vein endothelial cells. Blood 1992; 79:2930.

31. Mansoor MA, Bergmark C, Svardal AM, et al. Redox status and protein binding of plasma
homocysteine and other aminothiols in patients with early-onset peripheral vascular
disease. Homocysteine and peripheral vascular disease. Arterioscler Thromb Vasc Biol
1995; 15:232.

32. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen
peroxide generation from homocysteine. J Clin Invest 1986; 77:1370.
33. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are
modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin
Invest 1993; 91:308.

34. McCully KS, Carvalho AC. Homocysteine thiolactone, N-homocysteine thiolactonyl

retinamide, and platelet aggregation. Res Commun Chem Pathol Pharmacol 1987;
56:349.

35. Stühlinger MC, Tsao PS, Her JH, et al. Homocysteine impairs the nitric oxide synthase
pathway: role of asymmetric dimethylarginine. Circulation 2001; 104:2569.

36. Woo KS, Chook P, Lolin YI, et al. Hyperhomocyst(e)inemia is a risk factor for arterial
endothelial dysfunction in humans. Circulation 1997; 96:2542.

37. Kanani PM, Sinkey CA, Browning RL, et al. Role of oxidant stress in endothelial
dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation
1999; 100:1161.

38. Tawakol A, Omland T, Gerhard M, et al. Hyperhomocyst(e)inemia is associated with

impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95:1119.

39. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of
arteriosclerosis. Am J Pathol 1969; 56:111.

40. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role
of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58:731.

41. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. Vascular injury and arterial
thrombosis. N Engl J Med 1974; 291:537.

42. Rolland PH, Friggi A, Barlatier A, et al. Hyperhomocysteinemia-induced vascular damage

in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations.
Circulation 1995; 91:1161.

43. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell
growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 1994;
91:6369.

44. Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for

preventing cardiovascular events. Cochrane Database Syst Rev 2017; 8:CD006612.

45. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease
and stroke: a meta-analysis. JAMA 2002; 288:2015.
46. Humphrey LL, Fu R, Rogers K, et al. Homocysteine level and coronary heart disease
incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008; 83:1203.

47. Cheng SW, Ting AC, Wong J. Fasting total plasma homocysteine and atherosclerotic
peripheral vascular disease. Ann Vasc Surg 1997; 11:217.

48. Vasan RS, Beiser A, D'Agostino RB, et al. Plasma homocysteine and risk for congestive
heart failure in adults without prior myocardial infarction. JAMA 2003; 289:1251.

49. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C-->T polymorphism and risk of coronary
heart disease: a meta-analysis. JAMA 2002; 288:2023.

50. Kohara K, Fujisawa M, Ando F, et al. MTHFR gene polymorphism as a risk factor for silent
brain infarcts and white matter lesions in the Japanese general population: The NILS-LSA
Study. Stroke 2003; 34:1130.

51. van Meurs JB, Pare G, Schwartz SM, et al. Common genetic loci influencing plasma
homocysteine concentrations and their effect on risk of coronary artery disease. Am J Clin
Nutr 2013; 98:668.

52. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-
vein thrombosis. N Engl J Med 1996; 334:759.

53. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous

thromboembolic disease. Arch Intern Med 1998; 158:2101.

54. den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous
thrombosis: a meta-analysis. Thromb Haemost 1998; 80:874.

55. Eichinger S, Stümpflen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of

recurrent venous thromboembolism. Thromb Haemost 1998; 80:566.

56. Lijfering WM, Coppens M, van de Poel MH, et al. The risk of venous and arterial
thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant
thrombophilic defects. Thromb Haemost 2007; 98:457.

57. Lijfering WM, Veeger NJ, Brouwer JL, van der Meer J. The risk of venous and arterial
thrombosis in hyperhomocysteinemic subjects may be a result of elevated factor VIII
levels. Haematologica 2007; 92:1703.

58. Ospina-Romero M, Cannegieter SC, den Heijer M, et al. Hyperhomocysteinemia and Risk
of First Venous Thrombosis: The Influence of (Unmeasured) Confounding Factors. Am J
Epidemiol 2018; 187:1392.
59. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia
in women with complications of pregnancy. N Engl J Med 1999; 340:9.

60. Hague WM. Homocysteine and pregnancy. Best Pract Res Clin Obstet Gynaecol 2003;
17:459.

61. Ren A, Wang J. Methylenetetrahydrofolate reductase C677T polymorphism and the risk of
unexplained recurrent pregnancy loss: a meta-analysis. Fertil Steril 2006; 86:1716.

62. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine levels and the risk
of osteoporotic fracture. N Engl J Med 2004; 350:2033.

63. McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip
fracture in older persons. N Engl J Med 2004; 350:2042.

64. Dhonukshe-Rutten RA, Pluijm SM, de Groot LC, et al. Homocysteine and vitamin B12
status relate to bone turnover markers, broadband ultrasound attenuation, and fractures
in healthy elderly people. J Bone Miner Res 2005; 20:921.

65. Gerdhem P, Ivaska KK, Isaksson A, et al. Associations between homocysteine, bone
turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res 2007;
22:127.

66. Sawka AM, Ray JG, Yi Q, et al. Randomized clinical trial of homocysteine level lowering
therapy and fractures. Arch Intern Med 2007; 167:2136.

67. Smith AD, Refsum H, Bottiglieri T, et al. Homocysteine and Dementia: An International
Consensus Statement. J Alzheimers Dis 2018; 62:561.

68. Clarke R, Bennett D, Parish S, et al. Effects of homocysteine lowering with B vitamins on
cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. Am J
Clin Nutr 2014; 100:657.

69. Licking N, Murchison C, Cholerton B, et al. Homocysteine and cognitive function in

Parkinson's disease. Parkinsonism Relat Disord 2017; 44:1.

70. Christine CW, Auinger P, Joslin A, et al. Vitamin B12 and Homocysteine Levels Predict
Different Outcomes in Early Parkinson's Disease. Mov Disord 2018; 33:762.

71. Narayanan D, Luvai A, Barski R, Sharma R. Stroke in a young man. BMJ 2013;
347:f4484.

72. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of
cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 2006;
296:2720.
73. Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke
prevention: a meta-analysis. Lancet 2007; 369:1876.

74. Miller ER 3rd, Juraschek S, Pastor-Barriuso R, et al. Meta-analysis of folic acid

supplementation trials on risk of cardiovascular disease and risk interaction with baseline
homocysteine levels. Am J Cardiol 2010; 106:517.

75. Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteine-lowering therapy with
folic Acid in stroke prevention: a meta-analysis. Stroke 2010; 41:1205.

76. den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the
secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized,
placebo-controlled, double-blind trial. Blood 2007; 109:139.

77. Ray JG, Kearon C, Yi Q, et al. Homocysteine-lowering therapy and risk for venous
thromboembolism: a randomized trial. Ann Intern Med 2007; 146:761.

78. Li J, Huo Y, Qin X, et al. Efficacy of folic acid supplementation in primary prevention of
stroke among adults with hypertension in China. JAMA 2015; 313:1325.

79. Kang SS, Wong PW. Genetic and nongenetic factors for moderate
hyperhomocyst(e)inemia. Atherosclerosis 1996; 119:135.

80. Rosenson RS, Tangney CC. Preanalytical sources of measurement error: the conundrum
of the homocysteine hypothesis. Atherosclerosis 2007; 194:520.

81. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive
vascular disease. Annu Rev Nutr 1992; 12:279.

82. Kang SS. Treatment of hyperhomocyst(e)inemia: physiological basis. J Nutr 1996;

126:1273S.

83. Appel LJ, Miller ER 3rd, Jee SH, et al. Effect of dietary patterns on serum homocysteine:
results of a randomized, controlled feeding study. Circulation 2000; 102:852.

84. Dietrich M, Brown CJ, Block G. The effect of folate fortification of cereal-grain products on
blood folate status, dietary folate intake, and dietary folate sources among adult non-
supplement users in the United States. J Am Coll Nutr 2005; 24:266.

Topic 6837 Version 42.0

GRAPHICS

Pathways of homocysteine metabolism

Homocysteine is metabolized by one of two divergent pathways: transsulfuration and remethylation. The
transsulfuration of homocysteine to cysteine is catalyzed by CBS, a process that requires pyridoxal phosphate
(vitamin B6) as a cofactor. Remethylation of homocysteine produces methionine. This reaction is catalyzed either
by methionine synthase or by betainehomocysteine methyltransferase. Vitamin B12 (cobalamin) is the precursor
of methylcobalamin, which is cofactor for methionine synthase.

MS: methionine synthase; MTHFR: methylene tetrahydrofolate reductase; CBS: cystathionine-beta synthase; CL:
cystathionine-gamma-lyase; CHMT: betaine-homocysteine methyltransferase; DMG: dimethylglycine; B2: riboflavin; THF:
tetrahydrofolate; SAM: S-adenosyl methionine; SAH: S-adenosyl homocysteine.

Reprinted by permission from: Springer: Cardiovascular drugs and therapy. Kang SS, Rosenson RS. Analytic approaches
for the treatment of hyperhomocysteinemia and its impact on vascular disease. Cardiovasc Drugs Ther 2018; 32:233.
Copyright © 2018. https://link.springer.com/journal/10557.

Graphic 118333 Version 3.0

Contributor Disclosures
Robert S Rosenson, MD Grant/Research/Clinical Trial Support: Akcea [Lipids]; Amgen [Lipids
(Evolocumab)]; AstraZeneca [Antiplatelets (Ticagrelor)]; The Medicines Company [Lipids (Inclisiran)];
Novartis [Lipids]; Regeneron [Lipids (Evinacumab)]. Consultant/Advisory Boards: Akcea [Lipids]; Amgen
[Lipids]; Cordvidia [Antiinflammatory]; CVS Caremark; The Medicines Company [Lipids (Inclisiran)]. Equity
Ownership/Stock Options: MediMergent [Pharmacy claims database]. Other Financial Interests: Kowa
[Lipids (Pitavastatin)] honorarium; Amgen [Lipids (Evolocumab)]; Pfizer [Lipids (Atorvastatin)]; Regeneron
[Lipids (Alirocumab)]. C Christopher Smith, MD Nothing to disclose Kenneth A Bauer,
MD Consultant/Advisory Boards: Janssen Pharmaceuticals [Anticoagulation (Rivaroxaban)]. Mason W
Freeman, MD Nothing to disclose Jane Givens, MD Consultant/Advisory Boards (Partner): CVS
Health/CVS Omnicare [Pharmaceutical management of formulary decision-making].

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are
addressed by vetting through a multi-level review process, and through requirements for references to be
provided to support the content. Appropriately referenced content is required of all authors and must
conform to UpToDate standards of evidence.

Conflict of interest policy